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Abstract
Botulinum toxins (BoNTs) are the most potent toxins and are responsible for botulism, 
which is a neurological disease in man and animals. Botulism is characterized by flaccid 
paralysis and inhibition of secretions. BoNTs are produced by distinct clostridial species 
including Clostridium botulinum that consist in four physiological and genetic groups, 
atypical strains of C. baratii and C. butyricum. Recently, nonclostridial bacteria have been 
found to synthesize BoNTs. The particularity of BoNTs is to associate with nontoxic pro-
teins to form large-size complexes that are resistant to acidic pH and protease degrada-
tion of the digestive tract. BoNTs are divided into 10 types based on neutralization by 
specific antisera and into more than 40 subtypes according to their sequence variations. 
All BoNTs retain a common core structure and mode of action, which consists in the 
inhibition of neurotransmitter release, notably acetylcholine. Human botulism occurs 
in three main forms: foodborne botulism, botulism by intestinal colonization including 
infant botulism, and wound botulism. In France, type B foodborne botulism is the most 
prevalent form, resulting from the traditional consumption of pork products such as 
home-made cured ham. Albeit less frequent, human botulism is still present in France 
including diverse types and origins.
Keywords: botulism, botulinum toxin, Clostridium botulinum, flaccid paralysis
1. Introduction
Botulinum toxins (BoNTs) are the most potent toxins among bacterial, animal, and plant toxins. 
Indeed, the lethal activity as tested in laboratory animals by determining the lethal dose 50% 
(LD50) is the lowest compared to that of all other toxins. Because of its extreme lethal potency, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
BoNTs are considered as the greatest threat of toxin weapon and are classified as Category A 
threat agent by the Centers for Disease Control and Prevention Select Agent Program [1]. In 
the natural conditions, BoNTs are responsible for a neurological disease in man and animals, 
botulism, which is characterized by flaccid paralysis and inhibition of secretions. Outbreaks of 
animal botulism are worldwide distributed and cause important economic losses, notably in 
cattle and farmed birds. Human botulism is much rarer than animal botulism, but it is a severe 
disease often fatal without treatment. Human botulism is the most severe food poisoning, and 
botulism surveillance by health and food authorities is performed in most of the countries 
in order to rapidly identify and withdraw contaminated foods and also to address recom-
mendations to industrials and consumers regarding hygiene and food preservation practices. 
However, the paralytic effects of BoNTs are used in the treatment of numerous diseases includ-
ing muscle hyperactivity such as dystonia, strabismus, limb spasticity, sphincter dysfunction, 
or hypersecretion (hyperhidrosis, hypersialorrhea, and drooling in neurodegenerative dis-
eases), but also in the treatment of pain and in cosmetology. BoNTs are largely used as thera-
peutic drugs and are one of the drugs that have the most numerous medical indications [2, 3].
Botulism was described in the second part of the eighteenth century and at the beginning of the 
nineteenth century by Steinbuch (1817) and Kerner (1817–1822). Both described a particular form 
of foodborne poisoning due to ingestion of a “sausage poison.” An increased number of fatal 
food poisoning cases occurred at the end of eighteenth century in the southwest German region 
of Wurtenberg due to a decline in hygiene of rural food productions subsequently to Napoleonic 
war perturbations. The paralytic disease was mainly associated to the consumption of blood 
sausages and was termed “sausage poisoning.” This disease was also known as “Kerner’s dis-
ease” and the name “botulism” was coined later in the second half of the nineteenth century 
from the Latin word botulus meaning sausage [4]. Interestingly, albeit the nature of this poison-
ous substance was not known, Kerner envisioned the possibility of using this poison to treat 
diseases associated with an overactive nervous system, including muscle hyper-contraction and 
hyper-secretion of body fluids. Then in 1895, Emile Pierre Marie Van Ermengem, a professor of 
Microbiology at the University of Ghent and who had worked in the laboratory of Robert Koch 
in Berlin, isolated an anaerobic-sporulating microorganism that he had named Bacillus botulinus, 
from the ham, the intestine, and spleen of one of the victims of a severe outbreak of botulism 
which occurred in a small Belgian village (Ellezelles). The term Clostridium was then used to des-
ignate anaerobic spore-forming bacteria in contrast to Bacillus which was reserved for aerobic or 
facultative anaerobic bacteria. Subsequently, the other types of botulism with the identification 
and characterization of BoNTs and bacterial organism producers were reported [5].
2. Botulinum toxins
2.1. Structure
BoNTs share a common structure. They are synthesized as a precursor protein (about 150 kDa), 
which is inactive or weakly active. The precursor that does not contain a signal peptide is 
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released from the bacteria by a yet unknown mechanism. The precursor is proteolytically 
activated in the extra-bacterial medium either by Clostridium proteases or by exogenous pro-
teases such as digestive proteases in the intestinal content. The active neurotoxin consists of a 
light chain (L, about 50 kDa) and a heavy chain (H, about 100 kDa), which remain linked by 
a disulfide bridge. The structure of BoNTs shows three distinct domains: L-chain containing 
α-helices, and β-strands and including the catalytic zinc-binding protease motif (His-Glu-X-
X-His), the N-terminal part of the H-chain forming two unusually long and twisted α-helices, 
and the C-terminal part of the H-chain consisting of two distinct subdomains (HCN and HCC) 
involved in the recognition of the receptor. While the three domains are arranged in a linear 
manner in BoNT/A and BoNT/B, both the catalytic domain and the binding domain are on the 
same side of the translocation domain in BoNT/E. This domain organization in BoNT/E might 
facilitate a rapid translocation process [6–16].
The overall sequence identity at the amino acid level between BoNTs ranges from 34 to 
97%. Several domains are highly conserved which account for the common mode of action 
of these toxins including the central domains of L chains containing the catalytic site and 
the N-terminal half of the H-chains that is involved in the translocation of the L-chain into 
the cytosol. Thus, a similar mechanism of internalization of the intracellular active domain 
into target cells is shared by all the clostridial neurotoxins. In contrast, the C-terminal half 
of H-chain, mainly the HCC subdomains, is the most divergent [17–19]. This accounts for the different receptors recognized by the clostridial neurotoxins (see subsequent text).
2.2. Botulinum complexes
BoNTs associate by non-covalent bounds with non-toxic proteins (ANTPs) produced by 
C. botulinum to form large complexes of different sizes (medium M or 12S, large L or 16S, 
large-large LL or 19S), also known as progenitor toxins (Figure 1). Botulinum complexes are 
synthesized in in vitro cultures and in naturally contaminated food or intestinal content. The 
complexes are stable at acidic pH, but dissociates at alkaline pH (≥pH 7) (reviewed in [20]).
All BoNT complexes contain the non-toxic non-hemagglutinin (NTNH) protein. NTNH is 
highly conserved. Two main classes of botulinum complexes can be distinguished based on 
their composition in additional proteins, the botulinum complexes containing hemagglutinins 
(HAs, including HA33, HA17, and HA70) (HA-BoNT complexes) and those possessing OrfX 
(including OrfX1, Orfx2, and OrfX3) and P47 proteins (OrfX-BoNT complexes) [17, 20–23]. 
The composition and structure of HA-BoNT complexes have been extensively investigated, 
whereas the OrfX-BoNT complexes are still poorly characterized. The stoichiometry can vary 
according to the strain, culture conditions (culture media, temperature, period of culture, 
etc.), and the method of complex preparation [20]. C. botulinum A produces three types of 
botulinum complexes M (medium), L (large), and LL (large/large) [24, 25], whereas the other 
C. botulinum types yield only M and L complexes.
The 12S or M complex results from the association of a BoNT molecule together with a NTNH 
at a 1:1 ratio [26]. L HA-BoNT complexes of C. botulinum A, B, and C consist of BoNT/NTNH/
Botulinum Toxins, Diversity, Mode of Action, Epidemiology of Botulism in France
http://dx.doi.org/10.5772/intechopen.79056
3
HA70/HA17/HA33 in a molar ratio of 1:1:2:2:3 as determined by gel electrophoresis and den-
sitometry [27]. The HA33 are likely to be at the periphery of the complex. Using stain electron 
microscopy and single particle averaging analysis, a stoichiometry of 1:1:3:3:6 was deduced. 
L HA-BoNT complexes of C. botulinum A or B share a similar ovoid structure with three flex-
ible appendages, whereas the M OrfX-BoNT complex from C. botulinum E lacks these arms 
[25]. Further crystal structure analysis supports the 14 subunit complex of L HA-BoNT/A 
Figure 1. Genetic organization of ha-bont and OrfX-bont locus and structure of BoNT/A, NTNH, HA-NTNH-BoNT/A 
complex, OrfX2 and P47. L, BoNT light chain; H
N
, N-terminal part of BoNT heavy chain; HC, C-terminal part of BoNT heavy chain. The structure of OrfX-BoNT complex is not yet known.
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[24]. The LL complex produced only by C. botulinum A is presumed to be a dimer of the 
L complex linked by an oligomeric HA33 consisting of four molecules and thus containing 
two molecules of BoNT/A [21, 22, 28]. However, a refined analysis of LL complex showed a 
composition of 1 BoNT/A, 1 NTNH/A, 5–6 HA17, 4–5 HA23, 3–4 HA48, and 8–9 HA34 (HA23 
and HA48 resulting from HA70 nicking) [29].
The composition and organization of OrfX-BoNT complexes from C. botulinum A1, A2, and 
E is poorly characterized [30]. C. botulinum A2, A3, A4, A6, A7, A8, E, and F only produce M 
complexes devoid of hemagglutinating activity, and C. argentinense produces only L com-
plex [22]. M. botulinum complex type A2 only contains BoNT/A2 and NTNH, although P47, 
Orfx2, and OrfX3 are produced in the culture supernatant, but not OrfX1 or in very low 
amount [31]. OrfX1 has been detected in botulinum complex type E but not type F, whereas 
neither OrfX2 or P47 has been evidenced in both toxinotypes [32, 33]. The structure of 
OrfX2 and P47 showed a similarity with TULIP family of proteins which are lipid-binding 
proteins [34].
NTNHs from the different C. botulinum types retain a high identity level (76–83.5%) and are the 
most conserved proteins among the botulinum complex components [17, 20]. NTNH/A, NTNH/C, 
and NTNH/D contain a cleavage site within their N-terminus, yielding 15 kDa N-terminal and 
115 kDa C-terminal fragments. NTNH/A is split into 13 and 106 kDa fragments by cleavage 
between Pro144/Phe145 [35]. NTNH/C and NTNH/D are cleaved at Lys127 by a trypsin-like 
protease with 7–13 amino acids removed from the N-terminus of the 115 kDa fragment that 
subsequently results in three proteins starting at Leu135, Val139, or Ser141 [36]. NTNH is only 
cleaved in the 12S (M) complexes from C. botulinum types A, C, and D, but not in the L (16S) 
or LL (19S) complexes. The cleaved NTNH molecules constituted a nicked structure since the 
two fragments still remain together after NTNH purification [36]. In contrast, NTNH/E and 
NTNH/F show an identical deletion of 33 residues in the corresponding region of NTNH/A, 
NTNH/C, and NTNH/D encompassing the cutting site, and NTNH/G possesses a slightly dif-
ferent sequence in this region. It is presumed that the processing and additional sequence of 
NTNH in C. botulinum A, C, and D are responsible for forming 12S-, 16S-, and 19S-sized com-
plexes. The inability of C. botulinum E and F to form L complexes may result from the absence 
of hemagglutinin (HA) or other related proteins that bind to NTNH and from the absence of a 
putative binding site in NTNH/E and NTNH/F [17, 22].
BoNT and NTNH share a weak amino acid sequence identity (~20%), but both proteins retain 
a common structure (Figure 1). NTNH associates with BoNT by non-covalent bonds in a pH-
dependent manner to form an interlocked compact M complex, which is resistant to acidic 
pH and protease degradation, whereas each protein separately is sensitive to proteolysis 
[23, 25, 26, 37]. Thereby, NTNH is a non-toxic protein which acts as a chaperone protein to 
protect BoNT. NTNH does not contain the catalytic HExxH motif, but another zinc-binding 
motif, KCLIK, at the same position. Indeed, NTNH binds one zinc atom per each molecule but 
exhibits no proteolytic activity [38]. This strongly supports that all NTNH and BoNT variants 
derive from a common ancestor gene by duplication and subsequent independent reshuffling.
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HA33-35 is the most abundant hemagglutinin component of the HA-BoNT complexes. Type 
A HA35 binds to oligosaccharides containing galactose-β1-4glucose-N-acetyl-d-neuraminic 
acid (Galβ1-4GlcNAc) [39]. Thereby, hemagglutination induced by L and LL type A botulinum 
complexes is mainly mediated through HA35 binding to erythrocyte membrane glycolipids 
and glycoproteins containing Galβ1-4GlcNAc [39, 40]. Similarly, HA33 from types C and D 
botulinum complexes binds to paragloboside on Galβ1-4GlcNAc and also sialylglycolipids 
(GM3), as well as sialoglycoproteins (sialosylparagloboside) on the N-acetyl-d-neuraminic 
acid-α2-3-galactose-β1 motif [41]. The importance of HA33-35 in hemagglutination is also 
supported by monoclonal antibody studies. Type C-specific monoclonal antibodies against 
HA33 inhibit hemagglutination, contrary to those against HA50 and HA17 [42]. However, 
type C HA70 and its derivative HA50 recognize sialosylparagloboside and GM3 at the 
N-acetyl-d-neuraminic acid-α2-3-galactose-β1motif in erythrocyte membranes, like the cor-
responding L botulinum complex. Thus, HA50 could also be involved in hemagglutination 
[41]. HA35 purified from C. botulinum A is predominantly a dimeric, β-sheet protein in aque-
ous solutions. In C. botulinum A, five N-terminal amino acids are removed from HA35, but 
similar posttranslational modification has not been observed in HA33 from C. botulinum C. 
The significance of HA35 processing on its biological activity is not known [43]. It was first 
discovered that the 31 C-terminal amino acids, which contain a predicted carbohydrate rec-
ognition site, play an essential role in hemagglutination [44]. The structure of type C HA33 
shows two β-trefoil domains consisting of a six-stranded, antiparallel β-barrel capped on 
one side by three β-hairpins. Related β-trefoil structures bind to oligosaccharides and are 
found in other proteins, including various lectins like the ricin B-chain, cytokines, trypsin 
inhibitor, xylanase, as well as the C-terminal part of BoNTs. Type A and B HA35 retain a 
similar structure related to the carbohydrate-binding site of ricin, a plant toxin. It is worth 
noting that Asp263 and Asn285 of HA35, which are conserved in the lactose-binding site for 
ricin B chain, are critical for carbohydrate binding [45–47]. HA17 also adopts a β-trefoil fold, 
whereas HA70 forms a three-bladed propeller-like trimer with a pore located at the center 
of the trimer [48, 49].
More recently, a novel function has been attributed to HA complexes consisting in the disrup-
tion of intercellular junctions between intestinal epithelial cells. HAs recognize E-cadherin, 
which plays a crucial role in basolateral junction. The interaction of HAs with E-cadherin is 
species and isoform specific. Thereby, HAs directly bind to the extracellular domain of (epithe-
lial) E-cadherin, but not of (neural) N-cadherin, nor (vascular endothelial) VE-cadherin. Type B 
HAs specifically bind to human, bovine, and mouse E-cadherin but not to that of rat and chicken 
[50]. This is consistent with the fact that botulism type B is common in humans and is rarely 
observed in chickens. Type A BoNT complexes also recognize human E-cadherin, whereas type 
C BoNT complexes do not [50]. The combination of HAs (HA33, HA17, and HA50/70) orga-
nized in complex is required for the optimum binding to E-cadherin, whereas individual HAs 
do not interact with E-cadherin. HAs assemble in a threefold symmetric hetero-dodecameric 
structure, and the whole HA complex exhibits the highest affinity to E-cadherin. The minimal 
HA complex interacting with E-cadherin consists of domain 3 of HA70 (Pro-378-Asn-626), one 
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molecule of HA17, and two HA33 molecules [51]. HAs bind to the distal extracellular domain 
(EC1) of E-cadherin near the cadherin trans-dimer interface [50]. Thus, the HA-binding sites to 
carbohydrates and E-cadherin are functionally and structurally distinct [52].
The structures of OrfX2 and P47 are unrelated to that of HAs and show that they belong 
to the tubular lipid-binding (TULIP) protein superfamily. Thereby, OrfX1 and OrfX2 have 
been found to bind to phosphatidylinositol [34]. In contrast to HAs, OrfX proteins and OrfX 
complexes have not been reported to interact with E-cadherin or to alter the intestinal epithe-
lial barrier. This raises the question whether OrfX complexes are involved in BoNT passage 
through epithelial barriers. In C. botulinum strains type E, F, and some type A, BoNTs form 
complexes lacking HAs and are responsible for foodborne botulism, which is as severe as the 
classical type A and B botulism.
2.3. Botulinum toxin gene organization
The BoNT and ANTP genes are clustered in close vicinity in a DNA fragment which is called the 
botulinum locus. BoNT and ANTP genes are organized in two operons. The operon localized in 
the 3′ part of the botulinum locus contains ntnh-bont which is highly conserved in all C. botulinum 
strains. In C. botulinum types E and F and certain C. botulinum A strains, this operon contains an 
additional gene called p47 encoding a 47-kDa protein (Figure 1). The second operon consists of 
the ha or orfX genes and is localized upstream of the ntnh-bont operon. The ha or orfX operon is 
transcribed in opposite orientation to that of the ntnh-bont operon and shows more strain varia-
tion. In C. botulinum B, C, D, and some A strains, the ha operon consists of three genes (ha70, ha17, 
and ha33). The ha genes of C. botulinum G only comprise ha17 and ha70. The ha genes are missing 
in the non-hemagglutinating toxinotypes A1, A2, A3, A4, E, and F and an orfX operon (orfX1, 
orfX2, orfX3) instead of has lies upstream of the ntnh-bont operon [53–55] (Figure 1). It is worth 
noting that a same bont gene can be inserted into a HA or a OrfX locus. However, bont/A1 is the 
only gene which has been found in either of the two types of botulinum locus.
The botR gene encoding for an alternative sigma factor is a positive regulator of the ntnh-
bont and ha operons. botR is localized differently according to the C. botulinum strains, either 
between the ntnh-bont and ha operons or upstream of the ha operon. This gene is missing in C. 
botulinum E and toxigenic C. butyricum.
Most of C. botulinum strains produce only one type of BoNT, and the botulinum locus is pres-
ent in a single copy on the genome. However, some rare strains synthesize two different 
BoNTs: BoNT/A-BoNT/B, BoNT/A-BoNT/F, and BoNT/B-BoNT/F producing strains have 
been isolated. The two neurotoxins are usually produced in different proportions. Thus, in Ba 
and Bf strains, BoNT/B is produced 10 times more than BoNT/A and BoNT/F. Some clostridial 
strains contain silent neurotoxin genes. Several C. botulinum A strains isolated from foodborne 
and infant botulism contain a silent bontB gene. These strains are noted A(b). These strains 
contain two distinct botulinum loci. One C. botulinum strain has been found to harbor three 
botulinum loci containing bontA2, bontF4, and bontF5 [56].
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The botulinum loci are distributed on different genetic elements, including chromosome, 
plasmid, or phages depending on the species and strain of Clostridia. In C. argentinense, C. 
botulinum type B, mainly in subtype B1, bivalent, and non-proteolytic strains, and in some 
C. botulinum A strains, the botulinum loci are located on large plasmid. For example, in the 
bivalent strain Ba657, the two botulinum loci, locus A and locus B, are harbored by the same 
plasmid (pCLJ) separated by approximately 97 kbp. Similarly, the neurotoxin genes, bontB 
and bont/f, from one Bf strain are located on a same plasmid (pBf), which is very much related 
to pCLJ. In C. botulinum type E and neurotoxigenic C. butyricum strains, the bont/E loci are 
mainly on the chromosome. However, in three C. botulinum E strains from 36, bont/E1 is 
located on a large plasmid. In C. botulinum C and D, it has been clearly evidenced that BoNT 
is encoded by bacteriophages (reviewed in [57]).
The location of botulinum locus within chromosome or plasmid seems to occur not at random 
but at specific sites. Indeed, in strains from group I or II, whose genome sequencing is available, 
five specific sites of botulinum locus integration have been identified. orfX-bont/A2, orfX-bont/
A1, and orfXbont/F loci are located in the ars operon, which contains three to five genes involved 
in arsenic reduction. orfX-bont/A1 and orfX-bont/Floci share a similar integration site at the 5′ end 
of the ars operon, whereas orfx-bont/A2 locus is inserted between two copies of arsC gene. ha-
bont/A1 and ha-bont/B loci, which contain a recombinant ntnh gene type A and type B strains, are 
found in the oppA/brnQ operon, encoding for extracellular solute-binding protein and branched 
chain amino acid transport proteins, respectively. This operon is lacking in non-proteolytic C. 
botulinum type B, C. botulinum type E, and C. butyricum type E strains. The third integration site 
is the rarA gene in group II and V strains, which contains the orfX-bont/E locus in C. botulinum 
type E and C. butyricum type E strains. rarA encodes a resolvase protein involved in recombina-
tion or insertion events of transposons. Interestingly, the botulinum E locus is inserted in the 
same codon [102] of rarA gene in both C. botulinum type E and C. butyricum type E strains, and 
the inserted botulinum locus contains an additional intact rarA gene [58]. The trivalent strain 
A2f4f5 contains the orfX-bont/A2 and orfX-bont/F4 loci located in the chromosome at the arsC 
and pulE (type II secretion system protein E) genes, respectively [56]. In C. botulinum F, the orfX-
bont/F6 locus has been found in a new chromosomal integration site topE [59].
Two specific sites of botulinum locus location have been identified on plasmids from group I 
strains, one contains orfX-bont/A3, orfXbontT/A4 from Ba strain, or orfX-bontF from Bf strain, 
and the second harbors the ha-bont/B locus from C. botulinum B1 strain or bivalent Ba4 or Bf 
strains. The ha-bont/B4 locus in nonproteolytic strains is located on a plasmid different from 
those of group I strains. However, the downstream flanking region of the HA-npB locus con-
tains an IS element, a transposon-associated resolvase, and a site-specific recombinase [58]. It is 
worth noting that C. botulinum plasmids harboring bont genes such as pCLJ, pCLL, and pCDC-
A3 (related to pCLK) are transferable by conjugation into a group I C. botulinum strain [60].
The toxin gene location on the various genetic elements chromosome including mobile 
genetic elements (plasmid, phage) supports horizontal bont gene transfer between Clostridium 
strains and also between clostridia and non-clostridia strains. In addition, insertion sequences 
or transposases genes have been identified in the flanking regions of most of botulinum loci. 
These genetic elements are associated to gene mobility and contribute to the extreme plasticity 
of these BoNT-producing bacteria. It is worth noting that most of the insertion sequences are 
partially modified, suggesting a very ancient process of gene mobility and subsequent DNA 
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rearrangement or modification (review in [61–63]. Indeed, the BoNT-producing clostridia 
strains are heterogeneous and do not form a unique bacterial species. The C. botulinum spe-
cies has been designed on the basis of only one phenotype, the production of a paralytic toxin. 
However, it appeared that they show variable physiological and biochemical properties and 
they have been divided into four physiological groups (I–IV). Moreover, it was shown that 
atypical strains of other Clostridium species than C. botulinum such as C. baratii and C. butyri-
cum were able to synthesize a BoNT related to those produced by C. botulinum. Genetic analy-
sis including whole genome sequencing confirmed the distinction of the multiple groups and 
species of BoNT-producing bacteria [64–66]. More recently, bont genes have been found in the 
genome of non-clostridial species (see subsequently and in Table 1). Clostridia and other bac-
teria, which contain bont genes, are from the environment, raising intriguing question which 
Botulinum toxin 
type
BoNT/A BoNT/B BoNT/E BoNT/F
Subtypes A1, A2, A3, A4, A5, 
A6, A7, A8
B1, B2, B3, B5, B6, 
B7, B8
B4 E1, E2, E3, E6, 
E7, E8, E9, 
E10, E11, E12
F6 F2, F2, F3, 
F4, F5, F8
Enzymatic substrate 
(cleavage site)
SNAP25 (QR) VAMP1, 2, 3 (QF) SNAP25 (RI) VAMP1, 2, 3 
(QK)
F5: VAMP2 
(LE)
Neurotoxin-
producing bacteria
C. botulinum group I C. botulinum group II C. botulinum 
group I
Main physiological 
properties
Proteolytic
Lipase
Temperature growth: minimum 10–12°C, 
optimum 30–40°C
Highly heat-resistant spores
Non-proteolytic
Lipase
Growth at low temperature: 
minimum 2.5–3°C, optimum 
25–30°C
Moderate heat-resistant spores
Idem 
group I
Botulism Human, occasionally animal
Botulinum toxin 
type
BuNT/E BaNT/F BoNT/C BoNT/D BoNT/G BoNT/H
Subtypes E4, E5 F7 C/D, D/C G H or F/A or 
H/A
Enzymatic 
substrate 
(cleavage site)
SNAP25 (RI) VAMP2 (QK) SNAP25 (RA)
Syntaxin (KA)
VAMP1, 2, 3 
(KL)
VAMP1, 2, 3 
(AA)
VAMP1, 2, 3 
(LE)
Neurotoxin-
producing 
bacteria
C. butyricum C. baratii C. botulinum group III C. 
argentinense 
group IV
C. botulinum
group I
Main 
physiological 
properties
Non-
proteolytic
Glucidolytic
Lecithinase Non-proteolytic
Lipase
Temperature growth 37–40°C
No protease
No lipase
Group I
Botulism Human, animal not reported Animal, very rare in human No natural 
case reported
Human
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are the molecular mechanism and selection pressure of neurotoxin gene transfer and which 
are the advantages conferred by genes encoding paralytic toxins for higher organisms. It is 
worth noting that whether bont genes can be mobilized in diverse bacteria, their transfer is 
mainly restricted to Clostridium species.
2.4. Botulinum toxin diversity
BoNTs form a family of diverse proteins which share the common property to induce a flaccid 
paralysis. Historically, it was found that these toxins can be antigenically distinguished. On 
the basis of neutralization of the biological effects on small rodents with specific antisera, 
seven BoNT types (A–G) were identified. Each type-specific antitoxin only neutralizes the cor-
responding BoNT type. The differences in amino acid sequences range from 37.2 to 69.6% [19]. 
In 2013, a novel eighth BoNT type called H (or F/A or H/A) has been described from a bivalent 
C. botulinum strain isolated from an infant botulism case and producing both BoNT/B2 and 
Botulinum toxin 
type
BoNT/X BoNT/I or 
BoNT/Wo
BoNT/J or 
eBoNT/J or 
BoNT/En
Cp1 toxin (BoNT 
homolog)
BoNT/Ba
BoNT/Bf
BoNT/Ab
BoNT/Af
BoNT/A(B)
BoNT/A2F4F5
Subtypes Bivalent
BoNT/
B2-BoNT/X
Enzymatic 
substrate 
(cleavage site)
VAMP1, 2, 
3, 4, 5
Ypkt6 (RA)
VAMP2 (WW) VAMP2 (DL)
SNAP25, 23
(KD)
Syntaxin (MD)
?
Neurotoxin-
producing 
bacteria
C. botulinum 
strain 111
group I
Weissella 
oryzae
Enterococcus 
faecium
Chryseobacterium piperi Bivalent and 
trivalent
C. botulinum strains
Group I
Main 
physiological 
properties
Group I Gram-positive 
bacillus
Nonspore-
forming
Facultative 
anaerobic
Gram-positive 
cocci
Gram-negative bacillus
Strictly aerobic
Non-spore forming
Group I
Botulism Infant 
botulism 
Japan
No natural botulism case reported Human botulism
Table 1. Botulinum toxin (BoNT) types, subtypes, and their main properties including enzymatic substrates and cleavage 
sites, as well as the neurotoxin-producing microorganisms with their main physiological properties and involvement in 
naturally acquired botulism.
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BoNT/H [67, 68]. It was claimed that this novel BoNT type was not neutralized by the already 
known anti-BoNT sera justifying its assignment to a novel type. More recently, genome 
analysis showed the presence of a related bont sequence in an OrfX locus in C. botulinum type 
B strain 111 which also produces BoNT/B2. BoNT/X retains a low sequence identity with 
the other BoNT types, and it is not recognized by the antibodies against the previous BoNT 
types [69]. Moreover, bont-related sequences have been identified in non-clostridial bacte-
ria including Gram-positive/Gram-negative, spore-forming/non-spore-forming, anaerobic/
aerobic bacteria such as Weissella oryzae (BoNT/Wo or BoNT/I) from fermented rice [70], an 
Enterococcus faecalis strain (BoNT/J, or BoNT/En, or eBoNT/J) isolated from a cow [71, 72], and 
Chryseobacterium piperi (Cp1) from sediment [73] (Table 1). This suggests a complex and long 
evolution of bont genes, the ancestral source of which still remains mysterious [63, 74, 75].
An increased sequencing of bont genes and/or whole genome of individual strains shows that 
each BoNT type contains variable isoforms based on sequence variations. Therefore, BoNT 
types are divided into subtypes which were initially defined as displaying at least 2.6% amino 
acid sequence difference [76]. However, some BoNT subtypes, notably from types B and E, 
only exhibit 0.9–2.1% amino acid sequence difference, but they were assigned to distinct sub-
types according to phylogenetic clade analysis. Among more than 500 BoNT sequences, 41 
subtypes have been identified [19] (Table 1).
Amino acid sequence variations might impact BoNT biological functions including receptor 
recognition, the efficiency of entry into cells and persistence, recognition by monoclonal anti-
bodies, and enzymatic activity. For example, BoNT/A2 has been shown to enter more effi-
ciently into neuronal cells than BoNT/A1 and to have a higher affinity for its receptor [77, 78]. 
BoNT/A2 induces a faster paralysis than BoNT/A1/A4/A5, and BoNT/A3 has a shorter dura-
tion of effect [79]. In addition, BoNT/A2 retains a lower immunogenicity [80]. Thus, BoNT/
A2 would be a more efficient therapeutic agent than BoNT/A1 [81–83]. BoNT/A8 binds less 
efficiently to gangliosides embedded into a membrane and has a lower enzymatic activity than 
BoNT/A1 [84]. BoNT/B1 binds to synaptotagmin 1 and 2 receptors, whereas BoNT/B2 only 
recognizes synaptotagmin 2 [85]. In contrast to the BoNT/F subtypes which cleave VAMP1 
and VAMP2 at QK site, BoNT/F5 uses a distinct cleavage site (LE) [86] (Table 1). Monoclonal 
antibodies against BoNT/B differently recognize the subtypes BoNT/B1 to BoNT/B5 [87]. 
Similarly, monoclonal antibodies against BoNT/A recognize and/or neutralize the distinct 
BoNT/A subtypes with variable efficiently [88, 89].
3. Mode of action
BoNTs enter by oral route (foodborne botulism) or are produced directly in the intestine 
(infant or intestinal botulism) subsequently to a C. botulinum intestinal colonization. BoNTs 
are able to transcytose across the intestinal mucosa (review in [90] or can pass through the 
paracellular way with the help of HA complexes (review in [91]). After diffusion into the 
extracellular fluid and blood stream circulation, BoNTs target motoneuron endings.
Each type of BoNT and TeNT recognizes specific receptors on demyelinated terminal nerve 
endings, mainly through the HCC subdomain. BoNT/A/C/E/F exploit the three isoforms of 
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the vesicle protein SV2 as specific receptors, while BoNT/B and /G bind to synaptotagmin I 
or II [92–98]. BoNT/C and BoNT/D interact with gangliosides (GD
1b
, GT
1b
) and phosphatidyl-
ethanolamine, respectively, by their HCC subdomain [99]. Gangliosides (GD1b, GT1b, and GD2) and SV2A/B/C also mediate the entry of BoNT/D into neurons, but by a different mechanism 
than that used by BoNT/A and BoNT/E [100, 101]. The role of HCN subdomain, which may interact with phosphatidylinositol phosphates [102], is still unclear. The co-presence of the 
ad hoc ganglioside(s) and protein receptors likely facilitates the identification of cell subset 
targeted by BoNTs at very low concentrations encountered in the physiological medium dur-
ing the disease. At higher concentrations, binding to the protein receptor is likely sufficient for 
mediating toxin binding. Indeed, the number of cell types affected by these toxins expands 
with increasing toxin concentrations. Therefore, BoNTs can target numerous neurons but 
not all, as well as non-neuronal cells at high concentrations, inhibiting the release of various 
compounds.
Neurotoxin bound to its receptor is internalized by receptor-mediated endocytosis. Acidification 
of the vesicle lumen triggers a conformational change of the neurotoxin and subsequent trans-
location of the L chain into the cytosol. In addition, the disulfide bond between the two chains 
has a crucial role in the translocation process [103–106]. Then, the L chain refolds in the neutral 
pH of the cytosol. Cytosolic translocation factors such as β-COPI are possibly involved in this 
mechanism, as it has been found for diphtheria toxin [107–110].
L chains of all clostridial neurotoxins are zinc-metalloproteases that cleave one of the three 
members of the SNARE proteins. BoNT/B, D, F, and G attack synaptobrevin (or VAMP), 
BoNT/A and E cleaves SNAP25, and BoNT/C1 cut both SNAP25 and syntaxin. The cleavage 
sites are different for each neurotoxin. The cleavage of SNARE proteins occurs only when 
disassembled. Since VAMP, SNAP25, and syntaxin play a major role in the regulated fusion 
of synaptic vesicles with the plasma membrane at the release sites, their cleavage induces a 
blockade of the neurotransmitter exocytosis.
SNAP25 cleavage by BoNT/A or BoNT/E alters SNAP25 and synaptotagmin interaction, thus 
strongly reducing the responsiveness to Ca++ of exocytotic machinery [111–114]. Indeed, the 
removal of the nine C-terminal amino acids of SNAP-25 by BoNT/A deeply disrupts the cou-
pling between Ca2+ sensing and the final step in exocytosis [112]. Truncated SNAP-25 can 
behave as a dominant-negative mutant upon the exocytotic process, suggesting that after 
BoNT/A treatment, the block of release is due to both functional elimination of SNAP-25 and 
accumulation of the cleavage product which competitively inhibits exocytosis [115–117]. In 
contrast, the blockade of exocytosis by BoNT/E is only due to the elimination of functional 
SNAP-25 and not to the production of competitive antagonists of SNARE complex forma-
tion. Indeed, the inhibition of exocytosis by BoNT/E can be rescued by supplementing the 
C-terminal portion of SNAP-25 removed by the toxin [118–120]. Truncation of SNAP-25 by 
BoNT/E destabilizes the four-helix bundle of the SNARE complex [118, 119], and SNAP-25 
truncated by BoNT/E is not retained by syntaxin [121].
VAMP cleavage abolishes the interaction of VAMP with the adaptor protein AP3 and affects 
synaptic vesicle recycling via early endosomes [122]. The blockade of neuroexocytosis likely 
results from a disturbance of synaptophysin-1/VAMP2 interaction and of coupling between 
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detecting Ca2+ and synaptic vesicle triggering [112]. Since the synaptic vesicles docked with 
unproductive complexes cannot fuse or undock, they stay at the fusion sites (with slightly 
increased numbers), irreversibly plugging the fusion sites that would normally accommodate 
intact vesicles. This progressively reduces the number of active release sites to which exocyto-
sis can occur. When VAMP is cleaved by BoNT/B or /G, the VAMP portion (~20 amino acids) 
remaining in the synaptic vesicle membrane does not contain interaction sites for the other 
SNAREs. Therefore, the synaptic vesicle membrane is no longer linked to a SNARE complex, 
and fusion with the plasma membrane cannot occur. When VAMP is cleaved by BoNT/D or 
/F, the C-terminal fragment remaining in the vesicle membrane is long enough to anchor the 
synaptic vesicle to the SNARE complex, but fusion cannot occur because the SNARE complex 
cannot transit into the thermally stable four-helix bundle.
BoNT/C cleaves both syntaxin-1 and SNAP-25, but in vitro cleavage of SNAP-25 by BoNT/C 
occurs with a low efficiency (~1000-fold difference) versus cleavage by BoNT/A or /E [123, 124]. 
This raises the following question: which of the two targets is involved in BoNT/C neuroexo-
cytosis blockade?
Although the physiological properties induced by the cleavage of either VAMP, SNAP25, or 
syntaxin are not equivalent at the neuromuscular junctions, all the clostridial neurotoxins 
cause a blockade of the regulated neurotransmission, which varies in intensity and duration 
according to each neurotoxin type.
4. Epidemiology of botulism in France
4.1. Main clinical forms of human botulism
Several clinical forms of botulism are distinguished according to the mode of acquisition of BoNT 
and/or neurotoxigenic bacteria. Foodborne botulism occurs after the consumption of food con-
taminated by C. botulinum in which sufficient amount of toxin has been produced. Foods stored 
for a sufficient period such as home-made canned foods, home-fermented products, or commer-
cial minimally heated and chilled foods are at risk of botulism. Ingestion of preformed BoNT in 
food is responsible for botulism by intoxication. Foodborne botulism is the main form in adults.
Infant botulism results from the ingestion of C. botulinum spores that germinate, multiply, 
and produce BNT in the infants intestinal content. A low contaminating dose of 10–100 C. 
botulinum spores is sufficient to induce intestinal colonization and production of BoNT in the 
intestinal tract, since the intestinal microbiota, which has an inhibitory effect on the growth 
of C. botulinum in the digestive tract, might be not sufficiently developed or non-functional in 
babies under 1 year.
Botulism by intestinal colonization occasionally occurs in adults. Predisposing factors consist 
in factors that perturb or modify the microbiota composition such as antibiotherapy, intesti-
nal surgery 1 or 2 weeks prior consumption of a food contaminated by C. botulinum spores, 
chronic inflammation, and necrotic lesions of the intestinal mucosa, which might support the 
intestinal growth of C. botulinum.
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Wound botulism is caused by C. botulinum growth and toxin production in a contaminated 
wound or a lesion-like tetanus. Wound botulism is much rarer than tetanus. Drug users by 
injection who handle contaminated materials or drugs are notably at risk of wound botulism.
Inhalational botulism is very rare. A few cases have been reported in laboratory workers pre-
paring concentrated BoNT by continuous centrifugation and in two patients who inhaled 
cocaine (review in [125]). BoNT dissemination by aerosol has been considered as a possible 
bioterrorist attack.
Iatrogenic botulism is a recent novel form of botulism which develops subsequently to toxin 
overdoses for a therapeutic or a cosmetic purpose or to a hematological dissemination of toxin 
at a therapeutic dose.
4.2. Botulism in France
4.2.1. Foodborne botulism
The first case of human botulism was reported in 1875. The disease was very rare until the 
second war, since the consumption of canned foods was not traditional in France. This not 
excludes that the disease was underestimated or misdiagnosed. Only 24 cases were recorded 
from 1875 to 1936 and eight from 1936 to 1940 [126, 127]. In contrast, in the USA where the 
first industrial canned foods treated by heating were developed, large outbreaks of botulism 
occurred from 1899 to 1954, 514 outbreaks, 1350 cases including 861 deaths [127]. However, 
the incidence of botulism was very high in France during the Second World War. About 500 
outbreaks and 1000 cases were estimated between 1940 and 1944 [126]. Food deprivation and 
poor quality of home-made food preservation were the main factors responsible for this high 
incidence. Type B botulism predominated, and most of the incriminated foods (93%) were 
from pork meat, notably cured ham [126].
The incidence of botulism decreased after the Second World War (Figure 2). Albeit no sys-
tematic recording of botulism cases was performed during this period, only a few outbreaks 
were identified, mainly in the Anaerobe Laboratory of Pasteur Institute. During the period 
1956–1970, a 22.4 annual mean of botulism cases was observed based mainly on the detection 
of BoNT and/or C. botulinum in the incriminated food. Since 1971, the diagnosis of human 
botulism was improved by the detection of BoNT in patient’s serum [128]. Thus, the incidence 
of botulism increased to an annual mean of 76 cases per year within the 1971–1977 periods. 
This corresponds to a better survey of human botulism, but possibly also to the introduction 
of novel foods or modes of food preservation at risk of botulism, such as minimally heated and 
chilled foods or vacuum-packed chilled foods. Type B was the most frequent type of botulism 
(96.9% of outbreaks), and home-made or small-scale preparation of ham was the main source 
of botulism (63.7% of the outbreaks). However, commercial products or restaurant meals were 
incriminated or suspected in 30 (7.2%) outbreaks and were responsible for six deaths [129].
From 1986, human botulism is subjected to mandatory declaration to health authorities and 
since 1998 botulism declarations are coordinated by the national organism of disease survey 
InVS (Institut national de Veille Sanitaire called Sante Publique France since 2016). Since 1980, 
human botulism decreased, but every year, 10–40 cases are recorded in France. Home-made 
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preserved foods are less used but remain traditional in certain areas of France. Type B is pre-
dominant, and cured ham and pork meat preparations are the main origin of human botulism 
[130–135]. Pork is often a healthy carrier of C. botulinum type B and rarely develops botulism 
symptoms [136, 137]. Insufficient or inadequate sanitary measures in the preparation of pork 
meat and absence or insufficient heat treatment are the main risk factors. However, more 
diverse types and sources of botulism occurred since 2000 (Figure 2). Botulism type A, which 
was extremely rare in France, was more frequent since 1997 notably from canned vegetables 
[132]. Severe outbreaks of botulism type A occurred in 2008, one from commercial “enchi-
ladas” containing chicken meat, vegetables, and cereal cake, and another one from home-
made pumpkin jam [134]. During the period 2010–2012, botulism type A was predominant 
(23 cases out of 51) and resulted from diverse origins: home-made canned beans, commercial 
tapenades (olives, dried tomatoes), commercial pasta, and imported home-made eggplant 
preparation [135]. Only one outbreak of botulism type A (from home-made pheasant pie) was 
recorded within 2013–2016 [133].
Botulism type E is extremely rare in France. An outbreak of botulism type E occurred in 2009 
after the consumption of smoked and vacuum-packed fish which was bought a few days 
ago in Finland. The fish was from Canada and was processed in Finland [134]. In 2010, an 
unusual case resulted from a ham contaminated with C. botulinum B and a novel C. botulinum 
E subtype (E12) [135, 138]. It was hypothesized that marine salt used for the ham preparation 
could be the origin of the contamination.
Two atypical outbreaks of botulism type F occurred in 2014 and 2015. Both were Clostridium 
baratii F7 botulism. The first outbreak included two patients, one of which was totally para-
lyzed and showed a very high level of BoNT/F in the serum (400 mouse lethal doses/ml), 
Figure 2. Incidence of human botulism in France, 1875–2016. The numbers indicated in the period ranges 1875–1936, 
1940–1944, 1956–1970, and 1971–1977 are the annual mean values. Total cases (blue), type B botulism (green), type A 
botulism (red), type E botulism (purple), according to [127, 129–135, 147–151]. The two outbreaks of C. baratii type F 
botulism in 2014 and 2015 are not reported in the figure.
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but she recovered after 46 days in intensive care unit. The origin of this outbreak was not 
determined [139]. The second outbreak concerned three patients who have had their meal 
at the same restaurant on the same day. A Bolognese sauce prepared 2 days in advance with 
industrial ground meat was the common food. A sample of the ground meat in the refrigera-
tor of the restaurant was contaminated with C. baratii F7 [140, 141].
4.2.2. Infant botulism
Infant botulism is a rare form of botulism in France. Only 15 cases were identified from 2004 
to 2016. They resulted from group I C. botulinum type A or B and from different subtypes: 
A1(B), A2, Bf, B2, and B5. All food samples investigated for the origin of contamination were 
negative. In two outbreaks, an environmental contamination was strongly suspected. In one 
of them, the baby’s home was close to a reconstruction work. C. botulinum B was identified in 
stool sample of the baby and soil samples of the reconstruction work [133]. Another 2-month-
old baby developed botulism with several relapses over a period of 4 months. C. botulinum A2 
was isolated from stool samples all along the course of the disease. The particularity of this 
strain was its high resistance to penicillins and to metronidazole [142]. It was the first report 
of an antibiotic-resistant clinical C. botulinum strain. The baby’s home was at proximity of a 
thermal power station that intermittently released sprays of vapor and smoke/dust and that 
was suspected to be the origin of the contamination.
4.2.3. Wound botulism and inhalation botulism
Only one case of wound botulism was identified from 1995 to 2017. In 2008, a patient had 
an open fracture of the leg abroad and was hospitalized again when back to France for per-
sistent suppuration of the wound. He developed a type B botulism during the course of the 
second hospitalization [134]. Wound botulism in injection drug users was reported in several 
European countries and North America, but no such case was reported in France [143, 144]. 
However, in 2007, two patients who inhaled cocaine developed a botulism type B [145].
4.2.4. Botulism diversity in France
Albeit botulism is a rare disease, human botulism is identified every year in France. Foodborne 
botulism is the main form of botulism in France. Historically, home-made cured ham or pork 
products were the main source of type B botulism. During the recent period, home-made pre-
served foods including ham are no longer commonly used, but human botulism is still pres-
ent albeit to a lower extent than in the past. Thereby, the origin of botulism is more diverse 
including imported products, commercial minimally heated foods, or meals at a restaurant. 
The diversity of BoNT types and subtypes as well as of the BoNT-producing clostridia reflects 
the diverse origins of human botulism in France [146].
5. Conclusion
BoNTs form a wide diverse family of toxins which target specific neurons, leading to the inhi-
bition of release of neurotransmitters, notably acetylcholine. At least 10 BoNT types and more 
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than 40 subtypes have been identified. All BoNTs retain a common core structure and mode 
of action which consists in the inhibition of neurotransmitter release, notably acetylcholine, 
leading to flaccid paralysis. However, they use distinct pathways and distinct intracellular 
targets to drive the blockade of neurotransmission. Indeed, the distinct BoNT types recognize 
different neuronal receptors such as different sets of gangliosides and different membrane 
proteins (SV2 isoforms, synaptotagmin) and target either one of the three SNARE proteins at 
distinct cleavage sites. In addition, BoNTs are produced by diverse bacterial species, mainly 
from the Clostridium genus which are environmental bacteria. This raises the questions about 
the evolution and selection pressure involved in the emergence of so diverse bacterial proteins 
with unique function on the neurological system of higher eukaryotic organisms. BoNTs are 
responsible for severe neurological disease in man and animals which are still present in some 
countries such as in France. However, they also constitute valuable therapeutic tools for the 
treatment of diverse neurological dysfunctions. The increased number of medical indications 
of BoNTs contrasts with the high poisonous activity of these toxins. The wide BoNT diversity 
offers a panel of natural variants which can be adapted to specific applications.
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